Medicine and Dentistry
Patient
100%
Severe Acute Respiratory Syndrome Coronavirus 2
52%
Infection
37%
B Cell
35%
Influenza
34%
Therapeutic Procedure
31%
Antibody Response
30%
Fever
28%
Symptom
26%
Antibody
24%
Omicron Coronavirus Variant
22%
Highly Active Antiretroviral Therapy
19%
COVID-19
17%
Epithelial Cell
16%
Resident
16%
Hospital
15%
Vaccine
15%
Serum
15%
Influenza A Virus (H3N2)
13%
Allogeneic Hematopoietic Stem Cell Transplantation
13%
Drug Therapy
13%
Diagnosis
12%
Nursing Home
12%
Gene
11%
Enzyme Linked Immunosorbent Assay
11%
Combination Therapy
11%
Adverse Event
10%
Humoral Immunity
10%
Age
10%
Immunoglobulin G
10%
Influenza Virus
10%
Human Immunodeficiency Virus
9%
Analysis
9%
Injection
9%
Inpatient
9%
Woman
9%
Amino Acid
9%
Influenza A Virus (H1N1)
9%
Dendritic Cell
9%
Protein
9%
Interferon
8%
Diseases
8%
Sialidase Inhibitor
8%
Aciclovir
8%
Sialidase
8%
Quinolone
8%
Multigene Family
8%
RNA
8%
Faintness
8%
Systemic Lupus Erythematosus
8%
Pharmacology, Toxicology and Pharmaceutical Science
Influenza
51%
Virus
36%
Fever
32%
Influenza A Virus (H3N2)
29%
Extended Spectrum Beta Lactamase
27%
Quinolone
25%
Penicillinase
24%
Sialidase Inhibitor
24%
Oseltamivir
23%
Antipyretic Agent
22%
Infection
20%
Influenza A Virus (H1N1)
20%
Escherichia coli
19%
Bacterium
18%
Antibody
18%
Symptom
17%
Sialidase Inhibitor
16%
Cefepime
15%
IC50
14%
Laninamivir
13%
Sialidase
13%
Peramivir
12%
Vaccine
12%
Influenza Virus
12%
Baloxavir
11%
Hematologic Malignancy
11%
Adverse Event
10%
Antifungal Agent
10%
Relenza
10%
Antibiotic Resistance
9%
Sialidase
9%
Methicillin-Resistant Staphylococcus Aureus
9%
Klebsiella pneumoniae
9%
Oseltamivir
9%
Fungus Ball
8%
Vaccine Strain
8%
Bacilli
8%
Candidemia
8%
Nilotinib
8%
Pyrrole
8%
Faintness
8%
Baloxavir
8%
Influenza A (H3N2)
8%
Immunocompromised Patient
8%
IC50
8%
Influenza A Virus (H1N1)
7%
Live Attenuated Influenza Vaccine
6%
Viremia
6%
Bacteremia
6%
Glycine
6%
Immunology and Microbiology
Influenza
41%
Human Immunodeficiency Virus
40%
B Cell
40%
Mutation
36%
Influenza A Virus (H3N2)
30%
Sample
27%
Titer
26%
Monospecific Antibody
22%
Gene
22%
Vaccine Efficacy
20%
Spike
18%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
IC50
16%
Hemagglutinin
16%
Influenza Vaccine
15%
Wild Type
15%
Escherichia coli
15%
Breakthrough Infection
14%
Spectrum
14%
Helicobacter Cinaedi
12%
Cells
12%
Bacterium
12%
Influenza Virus
10%
Antibody Response
10%
Interferon Type I
10%
Virus
9%
B Cell Development
9%
Pressure
9%
Naive B Cell
9%
Dendritic Cell
9%
ELISA
9%
Fever
8%
Hypergammaglobulinemia
8%
Intravenous Immunoglobulin
8%
Transcription Factor GATA 1
8%
Tuberculin
8%
Multigene Family
8%
Fungus
8%
Urinary Tract
8%
Methicillin-Resistant Staphylococcus Aureus
8%
CXCR5
8%
Anion Exchange
8%
Hepatitis B Virus
8%
Systemic Lupus Erythematosus
8%
Bombyx Mori
8%
Omicron Coronavirus Variant
8%
Immunocompromised Patient
8%
Klebsiella pneumoniae
7%
Parotitis
7%
Time
6%
